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Introduction: Methotrexate (MTX) a folate antagonist is often given in high doses (≥500
mg/m2) to treat a variety of disease processes. While inpatient administration has been the
norm, outpatient administration, has been shown to be safe, effective, and patient
centered. Here in we describe development of an outpatient HDMTX protocol and our
initial experience.
Methods: All patients were to receive their ﬁrst cycle of HDMTX in the hospital to ensure
they tolerate it well and also to use this time to assist in training for home administration.
The outpatient protocol involved continuous IV sodium bicarbonate, along with oral
leucovorin and acetazolamide. Patients were required to visit the infusion center daily
for labs and methotrexate levels. Clear criteria for admission were developed in the case of
delayed clearance or methotrexate toxicity.
Results: Two patients completed the safety run-in phase. Both patients tolerated
treatment well. There were no associated toxicity. Methotrexate cleared within 3 days
for all cycles. Both patients were able to follow the preadmission instructions for sodium
bicarbonate and acetazolamide. The patients reported adequate teaching on the protocol
and were able to maintain frequency of urine dipstick checks.
Conclusion: We developed and implemented an outpatient protocol for high dose
methotrexate. This study largely details the development of this protocol and its initial
safety evaluation. More work needs to be done to assess its feasibility on a larger number
of patients who receive more cycles in the outpatient setting.
Keywords: health care delivery, diffuse large B cell lymphoma, CNS prophylactic treatment, quality improvement,
chemotherapy – oncology
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prophylaxis for diffuse large B-cell lymphoma (DLCBL). Herein
we present the development of our outpatient HDMTX protocol
and results of the safety run-in phase.

INTRODUCTION
Methotrexate (MTX) is a folate antagonist used across a wide range of
diseases, with dose levels classiﬁed as low or high (1). High-dose
methotrexate (HDMTX) consists of doses ≥500 mg/m2, used for the
treatment of primary and secondary CNS lymphoma (PCNSL),
leptomeningeal metastases, and osteosarcoma, as well as central
nervous system (CNS) prophylaxis in patients with leukemia and
high-risk lymphoma. These doses are potentially lethal without
administration of intravenous and/or oral leucovorin to rescue
normal cells from apoptosis, speciﬁcally in the bone marrow and GI
tract (2, 3). In addition to leucovorin, normal renal clearance of MTX is
required to quickly eliminate the drug, supported by aggressive
hydration and urinary alkalinization. Toxicities often occur as a
result of the high dose and duration of exposure, and include renal
toxicity, hepatotoxicity, stomatitis, myelosuppression, rash,
pneumonitis, and encephalopathy (4). To ensure safe administration,
HDMTX is most often administered in the hospital setting with an
average length of stay around 4-5 days, barring any treatment
complications. For patients receiving HDMTX for Primary CNS
lymphoma or CNS prophylaxis for DLBCL, these inpatient hospital
admissions, which most commonly are scheduled every 2 weeks, have
the potential to negatively impact a patient’s quality of life and
contribute to the growing ﬁnancial burden on the health care system.
There is experience with outpatient administration of HDMTX
in the pediatric population. Two small prospective studies, one in
pediatric acute lymphoblastic leukemia (ALL) and one in pediatric
osteosarcoma, showed the safety and feasibility of this approach in
the appropriate patient population, reducing cost and increasing
quality of life by allowing patients to remain out of the hospital (5,
6). Two large, retrospective studies in pediatric populations from
Memorial Sloan Kettering Cancer Center (MSKCC) and the
Children’s Hospital at Monteﬁore support these ﬁndings (7, 8).
While NCCN has published a toolkit to implement outpatient
HDMTX (9), few studies have been published and none of these
include the adult patient population, presenting a signiﬁcant gap in
the literature (10, 11). Studies are needed to examine the feasibility
and safety in this population, as comorbidities, organ dysfunction,
and social challenges seen in adults differ greatly from the pediatric
population (12).
Prior to the development of an outpatient HDMTX protocol in
the adult population, we performed a retrospective review of all
patients receiving inpatient HDMTX at Thomas Jefferson
University, an urban academic tertiary care medical center,
between January 1, 2018 and October 31, 2019 to determine the
distribution and rate of toxicities in adult patients at our institution.
Details of this study have been presented (13). The most common
toxicity observed in this population was acute kidney injury (AKI),
with an incidence of 21% in patients receiving HDMTX as
prophylaxis [median dose 3.5 g/m2 (1-3.5 g/m2)] compared to
33% in patients receiving HDMTX as treatment [median dose
3.5 g/m2 (range 0.25-12 g/m2)] for CNS disease. Additionally, all
AKI in the prophylactic group was grade II (>1.5 - 3.0 x baseline;
>1.5 - 3.0 x ULN) or lower according to CTCAE version 5.0 and
resolved. Other toxicities in patients receiving HDMTX for CNS
prophylaxis was minimal. Based on these results, we initiated an
outpatient HDMTX program in patients requiring CNS
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METHODS
We created an inter-professional, multi-disciplinary team to develop
the outpatient HD-MTX protocol. Our team included an oncologist,
oncology fellow, infusion center managers, nurse educators, inpatient
and outpatient nursing staff, advanced practice providers, oncology
pharmacists and home infusion service nurses and pharmacists.
Protocol development followed an iterative process and the ﬁnal
protocol is referenced in Appendix A. Once developed, the protocol
was implemented and modiﬁed through an iterative process with
each cycle of HD-MTX administered.
Complete patient eligibility criteria are listed in the protocol,
including a diagnosis of DLBCL requiring CNS prophylaxis (as
determined by their provider), age 18-70 years, ECOG
performance status ≤ 2, normal renal function (CrCl ≥60 mL/min),
no history of color blindness (to be able to read the urine dipstick),
and adequate social support. Patients who clear their ﬁrst
administration of HDMTX within 3-5 days without complications
qualify to receive cycles 2 and 3 in the outpatient setting. Both the
patient and caregiver are educated on reading the urine dipsticks.
While the optimal method of CNS prophylaxis has yet to be deﬁned
by prospective randomized studies, each patient receives a currently
accepted standard of 3 cycles of HDMTX at a dose of 3.5 gm/m2.
HDMTX can be given alternating with R-CHOP after even cycles (i.e.
2, 4, and 6) or at the end of 6 cycles of systemic treatment. All patients
complete cycle 1 of the protocol as an inpatient to ensure clearance of
the MTX without complications on the outpatient protocol.
During the inpatient stay for cycle 1, nursing and pharmacy
education is performed. Patients are taught how to use the urine
dipstick for pH monitoring. The frequency of monitoring is
discussed and reinforced. Scheduled medications are reviewed.
Pharmacists discuss with patients concomitant medications such
as sulfonamides, non-steroidal anti-inﬂammatory drugs, and proton
pump inhibitors should be avoided until after methotrexate
clearance. The home infusion team visits with the patient, ensures
insurance will cover all related costs, reviews the process for delivery
of materials and supplies and also provides an emergency number
for 24 hour access in case the infusion pump malfunctions or other
questions arise. Patients are also encouraged to call the cancer center
at any time to speak with a physician if any concerns or questions
arise during the home infusion process.
The protocol is initiated as follows. Oral sodium bicarbonate
1950mg every 6 hours and oral acetazolamide 500mg every 6 hours is
initiated at home, three and one days prior to MTX infusion,
respectively. On treatment day, patients receive HDMTX, given
over 4 hours, in the infusion center, and continuous IV ﬂuids with
normal saline (later changed to IV sodium bicarbonate allowing
discontinuation of oral sodium bicarbonate) through central venous
catheter is initiated. No recommendations were made on minimum
or maximum daily oral ﬂuid intake as the patient will receive the
necessary daily volume ofﬂuids intravenously. Patients monitor urine
pH at home via urine dipstick every 2 hours on day 1 followed by every
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4 hours thereafter while awake. Nightly acetazolamide 500mg is
continued, with additional dose every 6 hours as needed for urine
pH <7.5. Starting 24 hours after MTX infusion, patients begin oral
leucovorin 25 mg every 6 hours. A record is kept of side effects, timing
of medications, and urine pH levels (see Appendix B). Patients
present daily to the infusion center for toxicity check, medication
review, and blood draw including complete blood count,
comprehensive metabolic panel, and methotrexate levels (starting
on day 3, but this was later modiﬁed to day 2). Urine pH is checked
daily through central laboratory to ensure correlation with urine
dipsticks. Oral leucovorin is increased to 25mg every 3 hours as
needed based on the nomogram (Appendix C). According to our
standard of care practice, if the patient fails to show up for a scheduled
appointment, they will be called by the care team to investigate further.
Indications for admission to the hospital include serum Cr ≥1.5x
baseline, toxicity unable to be managed as outpatient, or need to
increase leucovorin dose to >25mg every 3 hours (given limit on oral
bioavailability) (14). Once methotrexate level is ≤0.1µmol/L, patients
are disconnected from IV ﬂuid infusion and stop oral acetazolamide.
Oral leucovorin is continued and oral sodium bicarbonate is restarted
for 3 additional days.
As part of the implementation process, a safety run-in phase
was designed such that the ﬁrst 5 cycles on the outpatient
protocol were administered in the inpatient setting. This runin was implemented to allow for any necessary changes to the
protocol to be made if unexpected barriers arose.

HDMTX has been published in pediatric populations, and a toolkit
has been suggested by NCCN, this protocol is one of the few
publication we are aware of detailing implementation of outpatient
HDMTX administration in adult patients. Our safety run-in phase
demonstrated feasibility and safety of the outpatient protocol for
patients with DLBCL requiring CNS prophylaxis, although we
acknowledge the small sample size (n=2) and young age of these
patients may bias the initial results. As the next phase of this
implementation initiative, a prospective observational study is
being performed with the primary objective to evaluate the rate of
methotrexate toxicity, particularly renal toxicity, in the outpatient
setting as compared to the rate of toxicity of our historical control.
Secondary objectives include comparing the effects on treatment
burden and cost burden for these care models, the total cost and outof-pocket cost for patients, as well as quality of life of inpatient versus
outpatient treatment modalities. This is being assessed through use of
the patient reported Treatment Burden Questionnaire (TBQ) (15),
the Cost Burden Survey (16), revenue cycle evaluation, and the
EORTC-qlq-c30 quality of life survey tool (17).
MSKCC has recently demonstrated feasibility of an outpatient
HDMTX protocol integrating glucarpidase into the treatment of
primary CNS lymphoma (18). Glucarpidase, a carboxypeptidase
enzyme, rapidly inactivates methotrexate to reduce toxicity without
crossing the blood brain barrier. Use of glucarpidase for this patient
population in the outpatient setting is appropriate given the high
risk of AKI and other toxicity seen in our retrospective analysis.
However, patients receiving HD-MTX for CNS prophylaxis are a
different patient population with lower risk for adverse events
including acute kidney injury and thus may not need
glucarpidase to effectively receive treatment as an outpatient as
has been described in these studies (10, 11). The use of glucarpidase
is often restricted to patients who meet speciﬁc criteria due to its
high cost. Our protocol aims to provide a patient centered approach
while at the same time limits cost and ﬁnancial burden of this
outpatient regimen. We recognize that our protocol requires
signiﬁcant effort and commitment on behalf of the patient and
their family, and is therefore limited to a subset of patients with
adequate social support and transportation resources. Additionally,
the success of outpatient chemotherapy care models requires a
supportive, multidisciplinary team.

RESULTS
Two patients completed the safety run-in phase. The ﬁrst patient,
a 46-year-old man with no comorbidities, received all three
cycles of HDMTX for CNS prophylaxis as an inpatient on the
outpatient protocol. Time to methotrexate clearance was ≤ 2
days for all three cycles. No AKI or other toxicity was observed.
During these cycles, the bedside urine dipsticks that were utilized
reported urine pH readings 0.5 higher than the lab urine pH. As a
result, an alternative urine dipstick test was used for the second
patient during the run-in phase.
The second patient, a 28-year-old man with no comorbidities,
received cycle 1 and 2 inpatient on the outpatient protocol, with
the third cycle completed outpatient. Time to methotrexate
clearance was ≤ 3 days for all three cycles. Again, no AKI or
other toxicity was observed. With the change in urine dipstick, the
lab-based pH values and those obtained at the bedside correlated.
Both patients were able to follow the preadmission instructions for
sodium bicarbonate and acetazolamide. The patients reported adequate
teaching on the protocol and were able to maintain frequency of urine
dipstick checks. Several logistical improvements were made to the
protocol based on patient feedback and process review.
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